Zolgensma: When Life Has a Price Tag

Zeba Gufran’s heart broke as she held her little boys, Erhan and Affan, in her arms. At five and seven years old, they should have been running around outside, playing tag and feeling the cool breeze against their skin. Their movements now, however, were weak and labored, their limbs floppy and unresponsive.

Erhan and Affan possessed Spinal Muscular Atrophy (SMA), a rare genetic disorder of the SMN1 gene that causes the depletion of the motor neuron protein “survival of motor neuron” (SMN). SMN plays a vital role in the proper gene expression of motor neurons; without it, patients experience a loss of motor neurons in the spinal cord, a consequence that prevents skeletal muscles from receiving inputs from nerve cells. When these muscles are not stimulated for an extended period of time, muscle atrophy, or the loss of muscle tissue, arises. The result is demonstrated by Erhan and Affan’s conditions: limited mobility, muscle weakness, difficulty breathing and swallowing, spontaneous tongue movements, and, at times, scoliosis (curvature of the spine).

Now, SMA is not an incurable disease. Treatments like Zolgensma, a one-dose gene therapy that replaces non-functional SMN1 genes with new copies, can potentially halt the progression of SMA, allowing patients to lead more mobile lives. It’s typically administered to children under the age of two, but the Gufran family was desperate for a miracle and willing to try whatever they could get their hands on. The problem with Zolgensma, however, was the cost. In India, a single dose of the drug is priced at 175 million rupees, or approximately $2.9 million CAD. Even if the Gufran family sold their home, exhausted their savings, and took out loans, they would still fall short of covering the expense of this vital treatment. 

The story of the Gufran family highlights a distressing reality faced by many families worldwide: the overwhelming cost of life-saving treatments, especially for rare diseases like SMA. Crowdfunding has become a lifeline for many, but it’s not a sustainable or fair solution. Thousands of patients are turning to social media and community fundraising efforts, hoping to raise enough money for their medications, operations, or therapies; yet because this approach often depends on the reach of a family’s story and the generosity of strangers, it leaves countless people unable to access the care they so desperately seek.

It’s evident that there currently exists a need for systemic solutions, such as government subsidies, better insurance coverage for rare diseases, and international collaborations to lower drug costs. Until these changes are made, countless families like the Gufrans will continue to face impossible choices, fighting not only SMA but also the financial barriers that prevent them from accessing the treatments they deserve. 

Sources:

doi: 10.1016/j.ncl.2015.07.004

doi: 10.7759/cureus.36197

https://www.bbc.com/news/world-asia-india-67259081